Teva Recalls Amikacin Sulfate Injection Due to Manufacturing Deviations
Teva Pharmaceuticals USA is voluntarily recalling 11,844 vials of Amikacin Sulfate Injection due to Current Good Manufacturing Practice (CGMP) deviations.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II. According to the rubric, FDA Class II recalls with potential for significant injury or property damage, or those involving structural defects or high-risk pathogens, are rated as Severe (4). While no specific injuries are reported, the classification and nature of the drug product warrant a Severe rating.
Plain-English summary
Teva Pharmaceuticals USA is voluntarily recalling 11,844 vials of Amikacin Sulfate Injection, USP, 1 gm/4 mL (250 mg/mL). The affected product is identified by NDC 0703-9040-01 (individual pack) and NDC 0703-9040-03 (shelf-pack carton of 10 vials). The recall was initiated on July 29, 2016, and was classified as Class II by the FDA.
The reason for the recall is Current Good Manufacturing Practice (CGMP) deviations. The affected lots are # 2381114, 2771114, and 4760915. The product was distributed nationwide and in Puerto Rico. The recall status is currently Terminated, with a termination date of February 5, 2018.
Healthcare providers and patients should check their inventory and records for the specific lot numbers listed above. If the product is found, it should be returned to the supplier or the recalling firm. No specific adverse health consequences are reported in the source text, but the recall is precautionary due to manufacturing quality issues.
The recalled product
- Product
- Amikacin Sulfate Injection, USP, 1 gm/4 mL (250 mg/mL) Rx Only, Manufactured in Hungary For: Teva Pharmaceuticals USA, Inc., North Wales, PA 19454, NDC 0703-9040-01 (individual pack), NDC 0703-9040-03 (shelf-pack carton of 10 vials).
- Manufacturer
- Teva Pharmaceuticals USA
- Category
- Drug — Antibiotic Injection
- Affected units
- 11,844
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (3)
- Lot # 2381114
- 2771114
- 4760915
Distribution
Part of a larger recall action
This product is one of 2 recalled by Teva Pharmaceuticals USA under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same manufacturer · Teva Pharmaceuticals USA
See all →- ModerateDoxylamine Succinate and Pyridoxine Hydrochloride Tablets Recalled for Failed Dissolution
FDA (Drugs) · 2022-02-09
- LowPrescription Drug Recall: Mimvey Mislabeling by Teva Pharmaceuticals
FDA (Drugs) · 2022-02-09
- ModerateTretinoin Capsules 10 mg Recalled for Failed Dissolution Specifications
FDA (Drugs) · 2022-02-09
- LowMimvey Estradiol/Norethindrone Prescription Drug Mislabeling Recall
FDA (Drugs) · 2022-02-09
- ModerateBrinzolamide Ophthalmic Suspension recalled for defective container caps
FDA (Drugs) · 2022-01-26
Same hazard · cgmp deviations
See all →- ModerateFentanyl Citrate Injectable Solution Recall Due to cGMP Deviations
FDA (Drugs) · 2026-05-06
- ModerateGlenmark Pharmaceuticals Recalls Pravastatin Sodium Tablets 80mg
FDA (Drugs) · 2025-04-16
- ModerateGlenmark Lacosamide 100mg Tablets Recalled for CGMP Deviations
FDA (Drugs) · 2025-04-16
- ModerateDrug Recall: APAP 500 mg Phenyl HCl Tablets for CGMP Deviations
FDA (Drugs) · 2022-02-16
- ModerateMigrenol Caplet Drug Recalled for CGMP Deviations
FDA (Drugs) · 2022-02-16